Increased expression of interleukin-1 receptor characterizes anti-estrogen-resistant ALDH(+) breast cancer stem cells
Sims, Andrew H
Hull, N J
Brown, M. E.
Brooks, M. D.
Wicha, M. S.
Howell, Sacha J
Clarke, Robert B
Simões, Bruno M
AffiliationManchester Breast Centre, Division of Cancer Sciences, University of Manchester, Manchester
MetadataShow full item record
AbstractEstrogen-receptor-positive breast tumors are treated with anti-estrogen (AE) therapies but frequently develop resistance. Cancer stem cells (CSCs) with high aldehyde dehydrogenase activity (ALDH+ cells) are enriched following AE treatment. Here, we show that the interleukin-1? (IL-1?) signaling pathway is activated in ALDH+ cells, and data from single cells reveals that AE treatment selects for IL-1 receptor (IL1R1)-expressing ALDH+ cells. Importantly, CSC activity is reduced by an IL1R1 inhibitor in AE-resistant models. Moreover, IL1R1 expression is increased in the tumors of patients treated with AE therapy and predicts treatment failure. Single-cell gene expression analysis revealed that at least two subpopulations exist within the ALDH+ population, one proliferative and one quiescent. Following AE therapy the quiescent population is expanded, which suggests CSC dormancy as an adaptive strategy that facilitates treatment resistance. Targeting of ALDH+IL1R1+ cells merits testing as a strategy to combat AE resistance in patients with residual disease. Keywords: ALDH(+) cells; IL1R1; anti-estrogens; breast cancer stem cells; dormancy.
CitationSarmiento-Castro A, Caamano-Gutierrez E, Sims AH, Hull NJ, James MI, Santiago-Gomez A, et al. Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH(+) Breast Cancer Stem Cells. Stem Cell Reports. 2020;15(2):307-16.
JournalStem Cell Reports
- The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.
- Authors: Januchowski R, Wojtowicz K, Zabel M
- Issue date: 2013 Sep
- Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.
- Authors: Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW
- Issue date: 2011 Jan
- Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
- Authors: Croker AK, Allan AL
- Issue date: 2012 May
- Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.
- Authors: Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Ohta K, Fukusumi T, Sakai D, Kudo T, Haraguchi N, Satoh T, Takiguchi S, Mori M, Doki Y, Ishii H
- Issue date: 2013 Apr
- Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
- Authors: Yang Z, Guo F, Albers AE, Sehouli J, Kaufmann AM
- Issue date: 2019 May